Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 3,403 Shares of Company Stock

Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CEO Leslie Trigg sold 3,403 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $3.67, for a total transaction of $12,489.01. Following the transaction, the chief executive officer directly owned 191,194 shares in the company, valued at $701,681.98. This trade represents a 1.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Price Performance

Shares of Outset Medical stock opened at $3.16 on Wednesday. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.86 and a quick ratio of 3.85. Outset Medical, Inc. has a fifty-two week low of $2.84 and a fifty-two week high of $6.49. The firm has a fifty day moving average price of $3.75 and a two-hundred day moving average price of $4.09. The company has a market cap of $59.63 million, a PE ratio of -0.82 and a beta of 1.93.

Outset Medical (NASDAQ:OM – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. The company had revenue of $33.60 million for the quarter, compared to analyst estimates of $31.40 million. Outset Medical had a negative net margin of 58.33% and a negative return on equity of 66.98%. Analysts expect that Outset Medical, Inc. will post -3.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on OM. Weiss Ratings lowered Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

View Our Latest Stock Report on Outset Medical

Institutional Investors Weigh In On Outset Medical

A number of institutional investors have recently bought and sold shares of OM. Marshall Wace LLP boosted its position in shares of Outset Medical by 128.0% during the 3rd quarter. Marshall Wace LLP now owns 483,380 shares of the company’s stock valued at $1,450,000 after acquiring an additional 271,387 shares in the last quarter. Empowered Funds LLC bought a new stake in Outset Medical in the third quarter valued at about $74,000. Squarepoint Ops LLC acquired a new position in Outset Medical in the second quarter worth about $98,000. Bank of New York Mellon Corp acquired a new position in Outset Medical in the second quarter worth about $121,000. Finally, Marquette Asset Management LLC bought a new position in Outset Medical during the second quarter worth about $212,000.

Outset Medical Company Profile

(Get Free Report)

Outset Medical is a medical technology company that develops and sells products for hemodialysis, a treatment that filters waste and excess fluid from the blood. Its main product is the Tablo Hemodialysis System, an integrated dialysis platform designed for use in hospitals, clinics and home settings. Tablo combines dialysis equipment with water purification and a touchscreen interface, aiming to simplify treatment setup and operation. The system also supports access to treatment data through connected software tools.

Recommended Stories

Insider Buying and Selling by Quarter for Outset Medical (NASDAQ:OM)

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.